CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
designed to evaluate the efficacy, safety, and tolerability of two doses of CT1812 compared to placebo in participants diagnosed with early Alzheimer's...
Phase 2
Philadelphia, Pennsylvania, United States and 29 other locations
This is a randomized, double-blind, sham-controlled, adaptive-design pivotal study of sensory stimulation in subjects with mild to moderate Alzheimer's...
Jenkintown, Pennsylvania, United States and 67 other locations
The reason for this study is to collect safety and efficacy information regarding the study drug remternetug in participants with early Alzheimer's...
Phase 3
Jenkintown, Pennsylvania, United States and 75 other locations
This study is designed to evaluate safety and efficacy of fosgonimeton (ATH-1017) in the treatment of mild to moderate Alzheimer's disease...
Phase 2, Phase 3
Norristown, Pennsylvania, United States of America and 89 other locations
This 52-week, open-label extension study is to evaluate the long-term safety and tolerability of ACP-204 in subjects with ADP.
Phase 3
Abington, Pennsylvania, United States and 6 other locations
This is a master protocol for 3 independent, seamlessly enrolling, multicenter, randomized, double-blind, placebo-controlled, parallel-group studies...
Phase 2, Phase 3
Abington, Pennsylvania, United States and 89 other locations
is superior to placebo on change from baseline of the Preclinical Alzheimer Cognitive Composite 5 (PACC5) at 216 weeks of treatment (A45 Tri...
Phase 3
Philadelphia, Pennsylvania, United States and 117 other locations
The purpose of this study is to assess the safety, tolerability and effect of study drug LY3372689 in participants with early symptomatic Alzheimer's...
Phase 2
Abington, Pennsylvania, United States and 69 other locations
Alzheimer's disease (AD) is a progressive, irreversible neurological disorder and is the most common cause of dementia in the elder...
Phase 2
Plymouth Meeting, Pennsylvania, United States and 36 other locations
administered once every four weeks (Q4W) in slowing cognitive and functional decline as compared to placebo in participants with early Alzheimer's...
Phase 2
Abington, Pennsylvania, United States and 96 other locations
Clinical trials
Research sites
Resources
Legal